1
|
Yan K, Yao J, Liu L, Liang W, Cai Y. Effects of low-frequency ultrasound combined with anti-MRSA agents on the mouse model of pulmonary infection. Microbiol Spectr 2024; 12:e0101623. [PMID: 38323827 PMCID: PMC10913739 DOI: 10.1128/spectrum.01016-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Accepted: 01/15/2024] [Indexed: 02/08/2024] Open
Abstract
The treatment of methicillin-resistant Staphylococcus aureus (MRSA)-induced pneumonia with antibiotics alone poses considerable challenges. To address these challenges, low-frequency ultrasound (LFU) emerges as a promising approach. In this study, a mouse pneumonia model was established through intratracheal injection of MRSA to investigate the therapeutic efficacy of LFU in combination with antibiotics. Minimal inhibitory concentration was assessed, and the distribution of antibiotics in the lung and plasma was determined using liquid chromatography coupled with mass spectrometry. Various parameters, including the survival rate, histopathology, lung bacterial clearance, and the expressions of cytokines and inflammation-related genes, were evaluated before and after treatment. Compared with the infection group, both the antibiotic-alone groups [vancomycin (VCM), linezolid, and contezolid (CZD)] and the groups in combination with LFU demonstrated an improvement in the survival status of mice. The average colony-forming units of lung tissue in the LFU combination groups were lower compared with the antibiotic-alone groups. While no significant changes in C-reactive protein and procalcitonin in plasma and bronchoalveolar lavage fluid were observed, histopathological results revealed reduced inflammatory damage in LFU combination groups. The secretion of interleukin-6 and tumor necrosis factor-alpha was decreased by the combination treatment, particularly in the VCM + LFU group. Furthermore, the expressions of MRSA virulence factors (hla and agrA) and inflammation-related genes (Saa3, Cxcl9, and Orm1) were further reduced by the combinations of LFU and antibiotics. Additionally, LFU treatment facilitated the distribution of VCM and CZD in mouse lung tissue at 30 and 45 min, respectively, after dosage.IMPORTANCETreating pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) with antibiotics alone poses significant challenges. In this in vivo study, we present compelling evidence supporting the efficacy of low-frequency ultrasound (LFU) as a promising approach to overcome these obstacles. Our findings demonstrated that LFU enhanced the effectiveness of vancomycin, linezolid, and contezolid in an MRSA pneumonia model. The combination of LFU with anti-MRSA agents markedly improved the survival rate of mice, accelerated the clearance of pulmonary bacteria, reduced inflammatory injury, inhibited the production of MRSA endotoxin, and enhanced the distribution of antibiotics in lung tissue. The application of LFU in the treatment of pulmonary infections held substantial significance. We believe that readers of your journal will find this topic of considerable interest.
Collapse
Affiliation(s)
- Kaicheng Yan
- Department of Pharmacy, Center of Medicine Clinical Research, Medical Supplies Center, Chinese PLA General Hospital, Beijing, China
- Unit 32701 of Chinese PLA, Beijing, China
| | - Jiahui Yao
- Department of Pharmacy, Center of Medicine Clinical Research, Medical Supplies Center, Chinese PLA General Hospital, Beijing, China
| | - Lingling Liu
- Department of Pharmacy, Center of Medicine Clinical Research, Medical Supplies Center, Chinese PLA General Hospital, Beijing, China
| | - Wenxin Liang
- Department of Pharmacy, Center of Medicine Clinical Research, Medical Supplies Center, Chinese PLA General Hospital, Beijing, China
| | - Yun Cai
- Department of Pharmacy, Center of Medicine Clinical Research, Medical Supplies Center, Chinese PLA General Hospital, Beijing, China
| |
Collapse
|
2
|
Kumar R, Mahata B, Gayathridevi S, Vipin Raj K, Vanka K, Sen SS. Lanthanide Mimicking by Magnesium for Oxazolidinone Synthesis. Chemistry 2024; 30:e202303478. [PMID: 37897110 DOI: 10.1002/chem.202303478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Revised: 10/26/2023] [Accepted: 10/27/2023] [Indexed: 10/29/2023]
Abstract
In the last decade, magnesium complexes have emerged as a viable alternative to transition-metal catalysts for the hydrofunctionalization of unsaturated bonds. However, their potential for advanced catalytic reactions has not been thoroughly investigated. To address this gap, we have developed a novel magnesium amide compound (3) using a PNP framework that is both bulky and flexible. Our research demonstrates that compound 3 can effectively catalyze the synthesis of biologically significant oxazolidinone derivatives. This synthesis involves a tandem reaction of hydroalkoxylation and cyclohydroamination of isocyanate using propargyl alcohol. Furthermore, we conducted comprehensive theoretical calculations to gain insights into the reaction mechanism. It is important to note that these types of transformations have not been reported for magnesium and would significantly enhance the catalytic portfolio of the 7th most abundant element.
Collapse
Affiliation(s)
- Rohit Kumar
- Inorganic Chemistry and Catalysis Division, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pashan, Pune, 411008, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - Biplab Mahata
- Inorganic Chemistry and Catalysis Division, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pashan, Pune, 411008, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - S Gayathridevi
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
- Physical and Materials Chemistry Division, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pashan, Pune, 411008, India
| | - K Vipin Raj
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
- Physical and Materials Chemistry Division, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pashan, Pune, 411008, India
| | - Kumar Vanka
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
- Physical and Materials Chemistry Division, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pashan, Pune, 411008, India
| | - Sakya S Sen
- Inorganic Chemistry and Catalysis Division, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pashan, Pune, 411008, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| |
Collapse
|
3
|
Green Synthesis of 2-Oxazolidinones by an Efficient and Recyclable CuBr/Ionic Liquid System via CO2, Propargylic Alcohols, and 2-Aminoethanols. Catalysts 2021. [DOI: 10.3390/catal11020233] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
With the aim of profitable conversion of carbon dioxide (CO2) in an efficient, economical, and sustainable manner, we developed a CuBr/ionic liquid (1-butyl-3-methylimidazolium acetate) catalytic system that could efficiently catalyze the three-component reactions of propargylic alcohols, 2-aminoethanols, and CO2 to produce 2-oxazolidinones and α-hydroxy ketones. Remarkably, this catalytic system employed lower metal loading (0.0125–0.5 mol%) but exhibited the highest turnover number (2960) ever reported, demonstrating its excellent activity and sustainability. Moreover, our catalytic system could efficiently work under 1 atm of CO2 pressure and recycle among the metal-catalyzed systems.
Collapse
|
4
|
An efficient and recyclable AgNO3/ionic liquid system catalyzed atmospheric CO2 utilization: Simultaneous synthesis of 2-oxazolidinones and α-hydroxyl ketones. J Catal 2021. [DOI: 10.1016/j.jcat.2020.11.011] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
5
|
Wu J, Cao G, Wu H, Chen Y, Guo B, Wu X, Yu J, Ni K, Qian J, Wang L, Wu J, Wang Y, Yuan H, Zhang J, Xi Y. Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers. Antimicrob Agents Chemother 2020; 64:e02158-19. [PMID: 32229495 PMCID: PMC7269508 DOI: 10.1128/aac.02158-19] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2019] [Accepted: 03/08/2020] [Indexed: 01/05/2023] Open
Abstract
Contezolid (MRX-I), a new oxazolidinone, is an antibiotic in development for treating complicated skin and soft tissue infections caused by resistant Gram-positive bacteria. This was a thorough QT study conducted in 52 healthy subjects who were administered oral contezolid at a therapeutic (800 mg) dose, a supratherapeutic (1,600 mg) dose, placebo, and oral moxifloxacin at 400 mg in four separate treatment periods. The pharmacokinetic profile of contezolid was also evaluated. Time point analysis indicated that the upper bounds of the two-sided 90% confidence interval (CI) for placebo-corrected change-from-baseline QTc (ΔΔQTc) were <10 ms for the contezolid therapeutic dose at each time point. The upper bound of the 90% CI for ΔΔQTc was slightly more than 10 ms with the contezolid supratherapeutic dose at 3 and 4 h postdose, and the prolongation effect on the QT/QTc interval was less than that of the positive control, moxifloxacin, at 400 mg. At 3 and 4 h after the moxifloxacin dose, the moxifloxacin group met the assay sensitivity criteria outlined in ICH Guidance E14 by having a lower confidence bound of ≥5 ms. The results of a linear exposure-response model which were similar to that of a time point analysis demonstrated a slightly positive relationship between contezolid plasma levels and ΔQTcF interval with a slope of 0.227 ms per mg/liter (90% CI, 0.188 to 0.266). In summary, contezolid did not prolong the QT interval at a therapeutic dose and may have a slight effect on QT interval prolongation at a supratherapeutic dose.
Collapse
Affiliation(s)
- Junzhen Wu
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China
- Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China
- National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
| | - Guoying Cao
- Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China
- National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
- Phase I Unit, Huashan Hospital, Fudan University, Shanghai, China
| | - Hailan Wu
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China
- Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China
- National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
| | - Yuancheng Chen
- Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China
- National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
- Phase I Unit, Huashan Hospital, Fudan University, Shanghai, China
| | - Beining Guo
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China
- Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China
- National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
| | - Xiaojie Wu
- Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China
- National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
- Phase I Unit, Huashan Hospital, Fudan University, Shanghai, China
| | - Jicheng Yu
- Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China
- National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
- Phase I Unit, Huashan Hospital, Fudan University, Shanghai, China
| | - Kanhong Ni
- Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China
| | - Jin Qian
- Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China
| | - Li Wang
- Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China
| | - Jufang Wu
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China
- Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China
- National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
- Phase I Unit, Huashan Hospital, Fudan University, Shanghai, China
| | - Yu Wang
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China
- Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China
- National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
| | - Hong Yuan
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China
- MicuRx Pharmaceuticals, Inc., Hayward, California, USA
| | - Jing Zhang
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China
- Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China
- National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
- Phase I Unit, Huashan Hospital, Fudan University, Shanghai, China
| | - Yuewen Xi
- Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China
| |
Collapse
|
6
|
New perspectives on the treatment of mycobacterial infections using antibiotics. Appl Microbiol Biotechnol 2020; 104:4197-4209. [PMID: 32185432 DOI: 10.1007/s00253-020-10513-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2019] [Revised: 02/22/2020] [Accepted: 02/28/2020] [Indexed: 12/13/2022]
Abstract
More than 100 years have passed since the discovery of Mycobacterium tuberculosis, in 1882, as the pathogen that causes tuberculosis (TB). However, globally, TB is still one of the leading causes of death by infectious diseases. In 2018, approximately 10.0 million people were diagnosed with TB owing to the development of advanced strategies by M. tuberculosis to resist antibiotics, including the development of a dormant state. The World Health Organization (WHO) and the Sustainable Development Goals (SDGs) are dedicated to ending TB by 2030. However, the development of strategies to discover new TB drugs and new therapies is crucial for the achievement of this goal. Unfortunately, the rapid occurrence of multidrug-resistant strains of M. tuberculosis has worsened the current situation, thereby warranting prioritized discovery of new anti-TB drugs and the development of new treatment regimens in academia and the pharmaceutical industry. In this mini review, we provide a brief overview of the current research and development pipeline for new anti-TB drugs and present our perspective of TB drug innovation. The data presented herein may enable the introduction of more effective medicines and therapeutic regimens into the market.Key Points• The Updated Global New TB Drug Pipelines are briefly summarized.• Novel strategies for the discovery of new TB drugs, including novel sources, bioinformatics, and synthetic biology strategies, are discussed.• New therapeutic options, including living therapeutics and phage therapy, are proposed.
Collapse
|
7
|
Methoxyphenyl N-sulfamoyloxazolidinone Cu(II) and Co(II) complexes: Synthesis, DFT/B3LYP (B2PLYP) study and molecular docking. J Mol Struct 2020. [DOI: 10.1016/j.molstruc.2019.127190] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
8
|
Wan N, Tian J, Zhou X, Wang H, Cui B, Han W, Chen Y. Regioselective Ring‐Opening of Styrene Oxide Derivatives Using Halohydrin Dehalogenase for Synthesis of 4‐Aryloxazolidinones. Adv Synth Catal 2019. [DOI: 10.1002/adsc.201900786] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Nanwei Wan
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of PharmacyZunyi Medical University Zunyi 563000 People's Republic of China
| | - Jiawei Tian
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of PharmacyZunyi Medical University Zunyi 563000 People's Republic of China
| | - Xiaoying Zhou
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of PharmacyZunyi Medical University Zunyi 563000 People's Republic of China
| | - Huihui Wang
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of PharmacyZunyi Medical University Zunyi 563000 People's Republic of China
| | - Baodong Cui
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of PharmacyZunyi Medical University Zunyi 563000 People's Republic of China
| | - Wenyong Han
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of PharmacyZunyi Medical University Zunyi 563000 People's Republic of China
| | - Yongzheng Chen
- Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of PharmacyZunyi Medical University Zunyi 563000 People's Republic of China
| |
Collapse
|
9
|
Li XD, Cao Y, Ma R, He LN. Thermodynamically favorable protocol for the synthesis of 2-oxazolidinones via Cu(I)-catalyzed three-component reaction of propargylic alcohols, CO2 and 2-aminoethanols. J CO2 UTIL 2018. [DOI: 10.1016/j.jcou.2018.01.022] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Song QW, Liu P, Han LH, Zhang K, He LN. Upgrading CO2
by Incorporation into Urethanes through Silver-Catalyzed One-Pot Stepwise Amidation Reaction. CHINESE J CHEM 2018. [DOI: 10.1002/cjoc.201700572] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Qing-Wen Song
- State Key Laboratory of Coal Conversion, Institute of Coal Chemistry; Chinese Academy of Sciences; Taiyuan Shanxi 030001 China
| | - Ping Liu
- State Key Laboratory of Coal Conversion, Institute of Coal Chemistry; Chinese Academy of Sciences; Taiyuan Shanxi 030001 China
| | - Li-Hua Han
- State Key Laboratory of Coal Conversion, Institute of Coal Chemistry; Chinese Academy of Sciences; Taiyuan Shanxi 030001 China
| | - Kan Zhang
- State Key Laboratory of Coal Conversion, Institute of Coal Chemistry; Chinese Academy of Sciences; Taiyuan Shanxi 030001 China
| | - Liang-Nian He
- State Key Laboratory and Institute of Elemento-Organic Chemistry; Nan-kai University; Tianjin 300071 China
| |
Collapse
|
11
|
Kim Y, Kim A, Lee S, Choi SH, Lee DY, Song JS, Lee H, Jang IJ, Yu KS. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects. Clin Ther 2017; 39:1849-1857. [PMID: 28865799 DOI: 10.1016/j.clinthera.2017.08.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2017] [Revised: 06/01/2017] [Accepted: 08/02/2017] [Indexed: 10/18/2022]
Abstract
PURPOSE Tedizolid phosphate is a next-generation oxazolidinone prodrug that is transformed into the active moiety tedizolid. Its indication is acute bacterial skin and skin structure infections caused by gram-positive species, including methicillin-resistant Staphylococcus aureus. Although tedizolid phosphate has been marketed in Korea, no data on the pharmacokinetic (PK) properties or tolerability of tedizolid phosphate in Korean subjects are available. This study was designed to evaluate the PK properties, oral bioavailability, and tolerability with a single-dose oral and intravenous administration of tedizolid phosphate in healthy Korean male subjects. METHODS A block-randomized, double-blind, placebo-controlled, single-dose study was conducted in 3 groups (200, 400, and 600 mg; 10 subjects in each group). In the second part of the study, subjects from the 200-mg group received administration orally and intravenously (1-hour infusion) via 2-way crossover for the evaluation of absolute bioavailability. There was a 7-day washout period between treatments in the absolute bioavailability part of the study. Serial blood samples for PK analysis were collected for up to 72 hours. Tolerability was assessed by analysis of adverse events. FINDINGS Thirty healthy Korean subjects completed the study and were included in the PK and tolerability analyses. Tedizolid phosphate was rapidly converted into tedizolid. After a single oral dose, the Tmax of tedizolid was observed to be 1.5 to 2.5 hours, and the plasma concentration-time curve of tedizolid showed a 2-phase elimination pattern, with a half-life of ~11 hours. Dose-dependent increases were observed in the AUClast value (29,441-78,062 μg · h/L) and in the Cmax value (2679-6980 μg/L) with the administration of tedizolid phosphate 200 to 600 mg PO. The absolute bioavailability of tedizolid was 95.2% (90% CI, 92.7%-97.8%) in the 200-mg administration group. There were no serious adverse events or clinically significant changes in the tolerability assessment. IMPLICATIONS Tedizolid phosphate at doses of up to 600 mg was well-tolerated in these healthy Korean male subjects. Tedizolid shows dose linearity with oral administration, and no dose adjustment of tedizolid phosphate 200 mg would be needed when switching administration routes. ClinicalTrials.gov identifier: NCT02097043.
Collapse
Affiliation(s)
- Yun Kim
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea
| | - Anhye Kim
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea; Clinical Trial Center, Ajou University Medical Center, Suwon, Republic of Korea
| | - SeungHwan Lee
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea
| | - Sung-Hak Choi
- Research Center, Dong-A ST Co., Ltd., Yongin, Republic of Korea
| | - Dae Young Lee
- Research Center, Dong-A ST Co., Ltd., Yongin, Republic of Korea
| | - Ji-Su Song
- Department of Clinical Development, Dong-A ST Co., Ltd., Seoul, Republic of Korea
| | - Howard Lee
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea; Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea
| | - In-Jin Jang
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea
| | - Kyung-Sang Yu
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
| |
Collapse
|
12
|
Li XD, Song QW, Lang XD, Chang Y, He LN. AgI
/TMG-Promoted Cascade Reaction of Propargyl Alcohols, Carbon Dioxide, and 2-Aminoethanols to 2-Oxazolidinones. Chemphyschem 2017; 18:3182-3188. [PMID: 28464505 DOI: 10.1002/cphc.201700297] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Revised: 04/17/2017] [Indexed: 11/10/2022]
Affiliation(s)
- Xue-Dong Li
- State Key Laboratory and Institute of Elemento-Organic Chemistry, College of Chemistry; Nankai University; Tianjin 300071 P.R. China
| | - Qing-Wen Song
- State Key Laboratory and Institute of Elemento-Organic Chemistry, College of Chemistry; Nankai University; Tianjin 300071 P.R. China
| | - Xian-Dong Lang
- State Key Laboratory and Institute of Elemento-Organic Chemistry, College of Chemistry; Nankai University; Tianjin 300071 P.R. China
| | - Yao Chang
- State Key Laboratory and Institute of Elemento-Organic Chemistry, College of Chemistry; Nankai University; Tianjin 300071 P.R. China
| | - Liang-Nian He
- State Key Laboratory and Institute of Elemento-Organic Chemistry, College of Chemistry; Nankai University; Tianjin 300071 P.R. China
- Collaborative Innovation Center of Chemical Science and Engineering; Nankai University; Tianjin 300071 P.R. China
| |
Collapse
|
13
|
Sebbar NK, Mekhzoum MEM, Essassi EM, Zerzouf A, Talbaoui A, Bakri Y, Saadi M, Ammari LE. Novel 1,4-benzothiazine derivatives: synthesis, crystal structure, and anti-bacterial properties. RESEARCH ON CHEMICAL INTERMEDIATES 2016. [DOI: 10.1007/s11164-016-2499-6] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
14
|
Song QW, Zhou ZH, Wang MY, Zhang K, Liu P, Xun JY, He LN. Thermodynamically Favorable Synthesis of 2-Oxazolidinones through Silver-Catalyzed Reaction of Propargylic Alcohols, CO2, and 2-Aminoethanols. CHEMSUSCHEM 2016; 9:2054-2058. [PMID: 27380740 DOI: 10.1002/cssc.201600470] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/11/2016] [Revised: 05/12/2016] [Indexed: 06/06/2023]
Abstract
Development of catalytic routes to incorporate CO2 into carbonyl compounds at mild conditions remains attractive and challenging. Herein, a one-pot three-component cascade reaction of terminal propargylic alcohols, CO2 , and 2-aminoethanols through Ag(I) -based catalysis is reported for the synthesis of carbonyl compounds through C-O/C-N bond formation. This thermodynamically favorable route can be ingeniously regulated to afford a wide range of 2-oxazolidinones along with concurrent production of α-hydroxyl ketone derivatives in excellent yields and selectivity. Preliminary mechanistic studies indicate that such a process proceeds through successive formation of α-alkylidene cyclic carbonate, β-oxopropylcarbamate, and 2-oxazolidinones.
Collapse
Affiliation(s)
- Qing-Wen Song
- State Key Laboratory and Institute of Elemento-Organic Chemistry, Nankai University, Tianjin, 300071, P.R. China
- State Key Laboratory of Coal Conversion, Institute of Coal Chemistry, Chinese Academy of Sciences, Taiyuan, 030001, P. R. China
| | - Zhi-Hua Zhou
- State Key Laboratory and Institute of Elemento-Organic Chemistry, Nankai University, Tianjin, 300071, P.R. China
| | - Mei-Yan Wang
- State Key Laboratory and Institute of Elemento-Organic Chemistry, Nankai University, Tianjin, 300071, P.R. China
| | - Kan Zhang
- State Key Laboratory of Coal Conversion, Institute of Coal Chemistry, Chinese Academy of Sciences, Taiyuan, 030001, P. R. China
| | - Ping Liu
- State Key Laboratory of Coal Conversion, Institute of Coal Chemistry, Chinese Academy of Sciences, Taiyuan, 030001, P. R. China
| | - Jia-Yao Xun
- State Key Laboratory of Coal Conversion, Institute of Coal Chemistry, Chinese Academy of Sciences, Taiyuan, 030001, P. R. China
| | - Liang-Nian He
- State Key Laboratory and Institute of Elemento-Organic Chemistry, Nankai University, Tianjin, 300071, P.R. China.
- Collaborative Innovation Center of Chemical Science and Engineering, Nankai University, Tianjin, 300071, P.R. China.
| |
Collapse
|
15
|
Mancuso R, Raut DS, Della Ca' N, Fini F, Carfagna C, Gabriele B. Catalytic Oxidative Carbonylation of Amino Moieties to Ureas, Oxamides, 2-Oxazolidinones, and Benzoxazolones. CHEMSUSCHEM 2015; 8:2204-2211. [PMID: 26089244 DOI: 10.1002/cssc.201500343] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/06/2015] [Revised: 05/08/2015] [Indexed: 06/04/2023]
Abstract
The direct syntheses of ureas, oxamides, 2-oxazolidinones, and benzoxazolones by the oxidative carbonylation of amines, β-amino alcohols, and 2-aminophenols allows us to obtain high value added molecules, which have a large number of important applications in several fields, from very simple building blocks. We have found that it is possible to perform these transformations using the PdI2 /KI catalytic system in an ionic liquid, such as 1-butyl-3-methylimidazolium tetrafluoroborate, as the solvent, the solvent/catalyst system can be recycled several times with only a slight loss of activity, and the product can be recovered easily by crystallization.
Collapse
Affiliation(s)
- Raffaella Mancuso
- Dipartimento di Chimica e Tecnologie Chimiche, Università della Calabria, Via Pietro Bucci, 12/C, 87036 Arcavacata di Rende (CS) (Italy).
- Dipartimento di Ingegneria Meccanica, Energetica e Gestionale, Università della Calabria, 87036 Arcavacata di Rende (CS) (Italy).
| | - Dnyaneshwar S Raut
- Dipartimento di Chimica e Tecnologie Chimiche, Università della Calabria, Via Pietro Bucci, 12/C, 87036 Arcavacata di Rende (CS) (Italy)
| | - Nicola Della Ca'
- Dipartimento di Chimica and CIRCC, Università di Parma, Parco Area delle Scienze 17 A, 43124 Parma (Italy)
| | - Francesco Fini
- Dipartimento di Scienze Biomolecolari, Università di Urbino, Piazza Rinascimento 6, 61029 Urbino (PU) (Italy)
| | - Carla Carfagna
- Dipartimento di Chimica Industriale "Toso Montanari", Università di Bologna, Viale Risorgimento 4, 40136 Bologna (Italy)
| | - Bartolo Gabriele
- Dipartimento di Chimica e Tecnologie Chimiche, Università della Calabria, Via Pietro Bucci, 12/C, 87036 Arcavacata di Rende (CS) (Italy).
| |
Collapse
|
16
|
Sanapala SR, Kulkarni SS. One-pot synthesis of bicyclic sugar oxazolidinone from d-glucosamine. RSC Adv 2015. [DOI: 10.1039/c5ra02270c] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Abstract
Herein we report a one-pot and efficient method for the synthesis of a 1,2-cis fused furanoside bicyclic oxazolidinone derivative of d-glucosamine via pyranose to furanose conversion and concomitant cyclization involving the N-Troc group.
Collapse
|
17
|
Fortuna CG, Berardozzi R, Bonaccorso C, Caltabiano G, Di Bari L, Goracci L, Guarcello A, Pace A, Palumbo Piccionello A, Pescitelli G, Pierro P, Lonati E, Bulbarelli A, Cocuzza CE, Musumarra G, Musumeci R. New potent antibacterials against Gram-positive multiresistant pathogens: Effects of side chain modification and chirality in linezolid-like 1,2,4-oxadiazoles. Bioorg Med Chem 2014; 22:6814-25. [DOI: 10.1016/j.bmc.2014.10.037] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2014] [Revised: 10/20/2014] [Accepted: 10/24/2014] [Indexed: 01/25/2023]
|
18
|
Krishna P, Srinivasulu D, Kotakadi VS. Synthesis, Characterization, and Antibacterial Activity of New Linezolid-Based Phosphoramidate Derivatives. PHOSPHORUS SULFUR 2014. [DOI: 10.1080/10426507.2014.902835] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- P. Krishna
- Department of Chemistry, Sri Venkateswara University, Tirupati -517502, Andhra Pradesh, India
| | - D. Srinivasulu
- Department of Chemistry, Sri Venkateswara University, Tirupati -517502, Andhra Pradesh, India
| | - Venkata S Kotakadi
- DST-PURSE Centre, Sri Venkateswara University, Tirupati -517502, Andhra Pradesh, India
| |
Collapse
|
19
|
Oxazolidinone derivatives: cytoxazone-linezolid hybrids induces apoptosis and senescence in DU145 prostate cancer cells. Eur J Med Chem 2014; 80:295-307. [PMID: 24793880 DOI: 10.1016/j.ejmech.2014.04.062] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2014] [Revised: 03/20/2014] [Accepted: 04/22/2014] [Indexed: 11/23/2022]
Abstract
In this study, we report the synthesis of novel oxazolidinone derivatives derived from linezolid 3 having p-methoxyphenyl group at C-4 position. In vitro evaluation for their anticancer activity toward cultured A549, DU145, HELA, and MCF7 were carried out. The series of compounds prepared displayed wide range of cytotoxicity in MTT assays (10-70 μM) across the cell lines tested. Of the all tested compounds 16 and 17 displayed good anticancer potential against A549 (lung) and DU145 (prostate) cancer cells. Further, to determine their anticancer potential, in the present study we have assessed effect of 17 on DU145 cells growth in in vitro assays. The results clearly demonstrated that the exposure of DU145 cells to 17 inhibits cell proliferation and induces apoptosis by activation of caspase-3 and -9. Long term exposure of DU145 cells to 17 induced cellular senescence confirmed by senescence marker β-galactosidase staining of cells on post exposure to 17. The results from this current report support that the oxazolidinone derivatives with ethyl and acryl substitutions showed promising anticancer activity which will be helpful to develop further novel anticancer agents with better therapeutic potential.
Collapse
|
20
|
Novel promising linezolid analogues: Rational design, synthesis and biological evaluation. Eur J Med Chem 2013; 69:779-85. [DOI: 10.1016/j.ejmech.2013.09.035] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2013] [Revised: 09/12/2013] [Accepted: 09/14/2013] [Indexed: 11/21/2022]
|
21
|
Maffioli SI. A Chemist's Survey of Different Antibiotic Classes. Antibiotics (Basel) 2013. [DOI: 10.1002/9783527659685.ch1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
22
|
New linezolid-like 1,2,4-oxadiazoles active against Gram-positive multiresistant pathogens. Eur J Med Chem 2013; 65:533-45. [DOI: 10.1016/j.ejmech.2013.03.069] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2012] [Revised: 02/25/2013] [Accepted: 03/31/2013] [Indexed: 11/22/2022]
|
23
|
Rai J, Randhawa GK, Kaur M. Recent advances in antibacterial drugs. Int J Appl Basic Med Res 2013; 3:3-10. [PMID: 23776832 PMCID: PMC3678679 DOI: 10.4103/2229-516x.112229] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2012] [Accepted: 10/08/2012] [Indexed: 11/15/2022] Open
Abstract
The incidence of antimicrobial resistance is on continued rise with a threat to return to the “pre-antibiotic” era. This has led to emergence of such bacterial infections which are essentially untreatable by the current armamentarium of available treatment options. Various efforts have been made to develop the newer antimicrobials with novel modes of action which can act against these multi-drug resistant strains. This review aims to focus on these newly available and investigational antibacterials approved after year 2000, their mechanism of actions/resistance, and spectrum of activity and their phases of clinical trials. Newer unexploited targets and strategies for the next generation of antimicrobial drugs for combating the drug resistance and emerging pathogens in the 21st century have also been reviewed in the present article.
Collapse
Affiliation(s)
- Jaswant Rai
- Department of Pharmacology, Govt. Medical College, Amritsar, Punjab, India
| | | | | |
Collapse
|
24
|
Synthesis, biological evaluation of new oxazolidino-sulfonamides as potential antimicrobial agents. Eur J Med Chem 2013; 62:661-9. [DOI: 10.1016/j.ejmech.2013.01.034] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2012] [Revised: 01/15/2013] [Accepted: 01/27/2013] [Indexed: 11/22/2022]
|
25
|
Lee K, Lee SH, Son JS, Ko SY, Lee SA, Lee KI. Potential Pitfalls of Using Epichlorohydrin as Starting Material for Oxazolidinone Antibacterials. B KOREAN CHEM SOC 2013. [DOI: 10.5012/bkcs.2013.34.2.641] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
26
|
Piccionello AP, Pierro P, Accardo A, Buscemi S, Pace A. Concise asymmetric synthesis of Linezolid through catalyzed Henry reaction. RSC Adv 2013. [DOI: 10.1039/c3ra45186k] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
27
|
Michalska K, Karpiuk I, Król M, Tyski S. Recent development of potent analogues of oxazolidinone antibacterial agents. Bioorg Med Chem 2012; 21:577-91. [PMID: 23273607 DOI: 10.1016/j.bmc.2012.11.036] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2012] [Revised: 11/16/2012] [Accepted: 11/19/2012] [Indexed: 11/24/2022]
Abstract
The oxazolidinones are a new and potent class of antimicrobial agents with activity mainly against Gram-positive strains. The commercial success of linezolid, the only FDA-approved oxazolidinone, has prompted many pharmaceutical companies to devote resources to this area of investigation. Until now, four types of chemical modifications of linezolid and oxazolidinone-type antibacterial agents, including modification on each of the A-(oxazolidinone), B-(phenyl), and C-(morpholine) rings as well as the C-5 side chain of the A-ring substructure, have been described. Division into sections according to side chain modification or the type of ring will be used throughout this review, although the process of synthesis usually involves the simultaneous modification of several elements of the linezolid substructure; therefore, assignment into the appropriate section depends on the structure-activity relationships (SAR) studies. This review makes an attempt to summarise the work carried out in the period from 2006 until mid-2012.
Collapse
Affiliation(s)
- Katarzyna Michalska
- Department of Antibiotics and Microbiology, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.
| | | | | | | |
Collapse
|
28
|
Bhattarai D, Lee SH, Seo SH, Nam G, Kang SB, Pae AN, Kim EE, Oh T, Cho SN, Keum G. Synthesis and In Vitro Antibacterial Activity of Novel 3-Azabicyclo[3.3.0]octanyl Oxazolidinones. Chem Biol Drug Des 2012; 80:388-97. [DOI: 10.1111/j.1747-0285.2012.01404.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Ji C, Lin W, Moraski GC, Thanassi JA, Pucci MJ, Franzblau SG, Möllmann U, Miller MJ. Syntheses and biological studies of novel spiropiperazinyl oxazolidinone antibacterial agents using a spirocyclic diene derived acylnitroso Diels-Alder reaction. Bioorg Med Chem 2012; 20:3422-8. [PMID: 22560837 PMCID: PMC3363956 DOI: 10.1016/j.bmc.2012.04.026] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2012] [Revised: 04/03/2012] [Accepted: 04/09/2012] [Indexed: 10/28/2022]
Abstract
Several novel oxazolidinone antibiotics with a spiropiperazinyl substituent at the 4'-position of the phenyl ring were synthesized through nitroso Diels-Alder chemistry and the in vitro antibacterial activities were evaluated against various Gram-positive bacteria (Bacillus subtilis, Staphylococcus aureus, Enterococcus faecalis), Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa) and mycobacteria (Mycobacterium vaccae, Mycobacterium tuberculosis). Analogs (8a and 12) were active against selected drug resistant microbes, like methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) and had no mammalian toxicity in a Hep-2 cellular assay (CC(50) >100 μM).
Collapse
Affiliation(s)
- Cheng Ji
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556
| | - Weimin Lin
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556
| | - Garrett C. Moraski
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556
| | - Jane A. Thanassi
- Achillion Pharmaceuticals, 300 George Street, New Haven, Connecticut, University of Illinois at Chicago, Chicago, Illinois 60612
| | - Michael J. Pucci
- Achillion Pharmaceuticals, 300 George Street, New Haven, Connecticut, University of Illinois at Chicago, Chicago, Illinois 60612
| | - Scott G. Franzblau
- Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612
| | - Ute Möllmann
- Leibniz Institute for Natural Product Research and Infection Biology - Hans Knoell Institute, Beutenbergstrasse 11a, 07745 Jena, Germany
| | - Marvin J. Miller
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556
| |
Collapse
|
30
|
Bhattarai D, Lee SH, Kim HK, Kang SB, Pae AN, Kim EEK, Oh TW, Cho SN, Keum GC. Synthesis and Antibacterial Activity of Novel 2-Oxo-pyrrolidinyl Oxazolidinones. B KOREAN CHEM SOC 2012. [DOI: 10.5012/bkcs.2012.33.4.1310] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
31
|
Palumbo Piccionello A, Musumeci R, Cocuzza C, Fortuna CG, Guarcello A, Pierro P, Pace A. Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives. Eur J Med Chem 2012; 50:441-8. [DOI: 10.1016/j.ejmech.2012.02.002] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2011] [Revised: 01/04/2012] [Accepted: 02/01/2012] [Indexed: 10/14/2022]
|
32
|
Pandit N, Singla RK, Shrivastava B. Current updates on oxazolidinone and its significance. INTERNATIONAL JOURNAL OF MEDICINAL CHEMISTRY 2012; 2012:159285. [PMID: 25954524 PMCID: PMC4412212 DOI: 10.1155/2012/159285] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/22/2011] [Revised: 10/16/2011] [Accepted: 10/20/2011] [Indexed: 11/17/2022]
Abstract
Oxazolidinone is a five-member heterocyclic ring exhibiting potential medicinal properties with preferential antibacterial activity. Scientists reported various synthetic procedures for this heterocyclic structure. Current review articles tried to cover each and every potential aspect of oxazolidinone like synthetic routes, pharmacological mechanism of action, medicinal properties, and current research activities.
Collapse
Affiliation(s)
- Neha Pandit
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Jaipur National University, Jagatpura-Jaipur, Rajasthan 302025, India
| | - Rajeev K. Singla
- Sadbhavna College of Management & Technology, Jalaldiwal, Ludhiana-Barnala State Highway-13, Raikot (Ludhiana), Punjab, India
| | - Birendra Shrivastava
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Jaipur National University, Jagatpura-Jaipur, Rajasthan 302025, India
| |
Collapse
|
33
|
Kanafani ZA, Corey GR. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin Investig Drugs 2012; 21:515-22. [PMID: 22324973 DOI: 10.1517/13543784.2012.660250] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Tedizolid phosphate (TR-701) is a new oxazolidinone prodrug that is transformed in the serum into the active drug tedizolid (TR-700). Tedizolid acts by inhibiting protein synthesis and has broad activity against Gram-positive pathogens, including strains that are resistant to linezolid. AREAS COVERED This review summarizes the currently available data on this new antimicrobial agent. In vitro activity, pharmacokinetics/pharmacodynamics, clinical efficacy and safety are all addressed. EXPERT OPINION Tedizolid will provide a useful addition to the antimicrobial armamentarium, particularly in complicated skin and skin structure infections, due to its high oral bioavailability and once-daily dosing. The results of future studies will serve to better position tedizolid among the newly approved agents for infections caused by Gram-positive organisms.
Collapse
|
34
|
Dong J, Karki SB, Parikh M, Riggs JC, Huang L. Oxidative degradation studies of an oxazolidinone-derived antibacterial agent, RWJ416457, in aqueous solutions. Drug Dev Ind Pharm 2012; 38:1289-97. [DOI: 10.3109/03639045.2011.648195] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
35
|
NIHONYANAGI S, ADACHI Y, ONUKI T, NAKAZAKI N, HIRATA Y, FUJIKI K, TAKAYAMA Y, KANOH Y, BANDOH Y, DANTSUJI Y, HANAKI H, SUNAKAWA K. Emergence of Linezolid-resistant Enterococcus faecalis Strains from Two Inpatients in a Pediatric Ward. ACTA ACUST UNITED AC 2012. [DOI: 10.11150/kansenshogakuzasshi.86.555] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Shin NIHONYANAGI
- Department of Medical Laboratory, Kitasato University Hospital
- Kitasato Institute for Life Science & Laboratory for Antimicrobial Agents, Kitasato University
| | - Yuzuru ADACHI
- Department of Medical Laboratory, Kitasato University Hospital
- Kitasato Institute for Life Science & Laboratory for Antimicrobial Agents, Kitasato University
| | - Tomoyo ONUKI
- Department of Medical Laboratory, Kitasato University Hospital
| | | | - Yasuyosi HIRATA
- Department of Infection Control & Prevention, Kitasato University Hospital
| | - Kuniko FUJIKI
- Department of Infection Control & Prevention, Kitasato University Hospital
| | - Yoko TAKAYAMA
- Department of Infection Control & Prevention, Kitasato University Hospital
| | - Yuhsaku KANOH
- Department of Medical Laboratory, Kitasato University Hospital
- Department of Laboratory Medicine, Kitasato University
| | - Yuki BANDOH
- Department of Pediatrics, Kitasato University
| | - Yurika DANTSUJI
- Kitasato Institute for Life Science & Laboratory for Antimicrobial Agents, Kitasato University
| | - Hideaki HANAKI
- Kitasato Institute for Life Science & Laboratory for Antimicrobial Agents, Kitasato University
| | - Keisuke SUNAKAWA
- Department of Infection Control & Prevention, Kitasato University Hospital
- Kitasato Institute for Life Science & Graduate School of Infection Control Science, Kitasato University
| |
Collapse
|
36
|
Kim CR, Ko SY. Glycidyl Tosylate is a Viable Starting Material for Oxazolidinone Antibacterials. B KOREAN CHEM SOC 2011. [DOI: 10.5012/bkcs.2011.32.12.4450] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
37
|
Billal DS, Feng J, Leprohon P, Légaré D, Ouellette M. Whole genome analysis of linezolid resistance in Streptococcus pneumoniae reveals resistance and compensatory mutations. BMC Genomics 2011; 12:512. [PMID: 22004526 PMCID: PMC3212830 DOI: 10.1186/1471-2164-12-512] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2011] [Accepted: 10/17/2011] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Several mutations were present in the genome of Streptococcus pneumoniae linezolid-resistant strains but the role of several of these mutations had not been experimentally tested. To analyze the role of these mutations, we reconstituted resistance by serial whole genome transformation of a novel resistant isolate into two strains with sensitive background. We sequenced the parent mutant and two independent transformants exhibiting similar minimum inhibitory concentration to linezolid. RESULTS Comparative genomic analyses revealed that transformants acquired G2576T transversions in every gene copy of 23S rRNA and that the number of altered copies correlated with the level of linezolid resistance and cross-resistance to florfenicol and chloramphenicol. One of the transformants also acquired a mutation present in the parent mutant leading to the overexpression of an ABC transporter (spr1021). The acquisition of these mutations conferred a fitness cost however, which was further enhanced by the acquisition of a mutation in a RNA methyltransferase implicated in resistance. Interestingly, the fitness of the transformants could be restored in part by the acquisition of altered copies of the L3 and L16 ribosomal proteins and by mutations leading to the overexpression of the spr1887 ABC transporter that were present in the original linezolid-resistant mutant. CONCLUSIONS Our results demonstrate the usefulness of whole genome approaches at detecting major determinants of resistance as well as compensatory mutations that alleviate the fitness cost associated with resistance.
Collapse
Affiliation(s)
- Dewan S Billal
- Centre de recherche en Infectiologie du Centre de recherche du CHUL, Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Canada
| | | | | | | | | |
Collapse
|
38
|
McCluskey SM, Knapp CW. Predicting antibiotic resistance, not just for quinolones. Front Microbiol 2011; 2:178. [PMID: 21909335 PMCID: PMC3164100 DOI: 10.3389/fmicb.2011.00178] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2011] [Accepted: 08/16/2011] [Indexed: 11/13/2022] Open
Affiliation(s)
- Seánín M McCluskey
- Department of Civil Engineering, David Livingstone Centre for Sustainability, University of Strathclyde Glasgow, UK
| | | |
Collapse
|
39
|
Im WB, Choi SH, Park JY, Choi SH, Finn J, Yoon SH. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur J Med Chem 2011; 46:1027-39. [DOI: 10.1016/j.ejmech.2011.01.014] [Citation(s) in RCA: 94] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2010] [Revised: 12/31/2010] [Accepted: 01/11/2011] [Indexed: 10/18/2022]
|
40
|
Rezende P, Paioti PHS, Coelho F. Diastereoselective Approach to Substituted Oxazolidinones from Morita–Baylis–Hillman Adducts. SYNTHETIC COMMUN 2010. [DOI: 10.1080/00397910903534023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Patrícia Rezende
- a Laboratory of Synthesis of Natural Products and Drugs, Department of Organic Chemistry , Chemistry Institute, University of Campinas , Campinas, Brazil
| | - Paulo H. S. Paioti
- a Laboratory of Synthesis of Natural Products and Drugs, Department of Organic Chemistry , Chemistry Institute, University of Campinas , Campinas, Brazil
| | - Fernando Coelho
- a Laboratory of Synthesis of Natural Products and Drugs, Department of Organic Chemistry , Chemistry Institute, University of Campinas , Campinas, Brazil
| |
Collapse
|
41
|
Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother 2010; 54:5337-43. [PMID: 20837751 DOI: 10.1128/aac.00663-10] [Citation(s) in RCA: 108] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Staphylococcal resistance to linezolid (LZD) is mediated through ribosomal mutations (23S rRNA or ribosomal proteins L3 and L4) or through methylation of 23S rRNA by the horizontally transferred Cfr methyltransferase. To investigate the structural basis for oxazolidinone activity against LZD-resistant (LZD(r)) strains, we compared structurally diverse, clinically relevant oxazolidinones, including LZD, radezolid (RX-1741), TR-700 (torezolid), and a set of TR-700 analogs (including novel CD-rings and various A-ring C-5 substituents), against a panel of laboratory-derived and clinical LZD(r) Staphylococcus aureus strains possessing a variety of resistance mechanisms. Potency against all strains was correlated with optimization of C- and D-rings, which interact with more highly conserved regions of the peptidyl transferase center binding site. Activity against cfr strains was retained with either hydroxymethyl or 1,2,3-triazole C-5 groups but was reduced by 2- to 8-fold in compounds with acetamide substituents. LZD, which possesses a C-5 acetamide group and lacks a D-ring substituent, demonstrated the lowest potency against all strains tested, particularly against cfr strains. These data reveal key features contributing to oxazolidinone activity and highlight structural tradeoffs between potency against susceptible strains and potency against strains with various resistance mechanisms.
Collapse
|
42
|
Renslo AR. Antibacterial oxazolidinones: emerging structure-toxicity relationships. Expert Rev Anti Infect Ther 2010; 8:565-74. [PMID: 20455685 DOI: 10.1586/eri.10.26] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The oxazolidinones are an important class of synthetic bacterial protein synthesis inhibitors with activity against Gram-positive and some fastidious Gram-negative bacteria. Key toxicological issues with the class include reversible inhibition of monoamine oxidase enzymes and reversible myelosuppression that can occur in patients treated for longer than the recommended course of therapy. Recent studies have uncovered the likely molecular mechanism underlying oxazolidinone-related myelosuppression and other toxicities, and these will be discussed here. Also reviewed are recent reports of structural modifications that can attenuate one or more of the undesired effects of oxazolidinones, while retaining the desired antibacterial effect.
Collapse
Affiliation(s)
- Adam R Renslo
- Department of Pharmaceutical Chemistry and the Small Molecule Discovery Center, University of California, San Francisco, 1700 4th Street, San Francisco, CA 94158, USA.
| |
Collapse
|
43
|
Linezolid Resistance in Staphylococci. Pharmaceuticals (Basel) 2010; 3:1988-2006. [PMID: 27713338 PMCID: PMC4036669 DOI: 10.3390/ph3071988] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2010] [Revised: 06/03/2010] [Accepted: 06/23/2010] [Indexed: 11/21/2022] Open
Abstract
Linezolid, the first oxazolidinone to be used clinically, is effective in the treatment of infections caused by various Gram-positive pathogens, including multidrug resistant enterococci and methicillin-resistant Staphylococus aureus. It has been used successfully for the treatment of patients with endocarditis and bacteraemia, osteomyelitis, joint infections and tuberculosis and it is often used for treatment of complicated infections when other therapies have failed. Linezolid resistance in Gram-positive cocci has been encountered clinically as well as in vitro, but it is still a rare phenomenon. The resistance to this antibiotic has been, until now, entirely associated with distinct nucleotide substitutions in domain V of the 23S rRNA genes. The number of mutated rRNA genes depends on the dose and duration of linezolid exposure and has been shown to influence the level of linezolid resistance. Mutations in associated ribosomal proteins also affect linezolid activity. A new phenicol and clindamycin resistance phenotype has recently been found to be caused by an RNA methyltransferase designated Cfr. This gene confers resistance to lincosamides, oxazolidinones, streptogramin A, phenicols and pleuromutilins, decrease the susceptibility of S. aureus to tylosin, to josamycin and spiramycin and thus differs from erm rRNA methylase genes. Research into new oxazolidinones with improved characteristics is ongoing. Data reported in patent applications demonstrated that some oxazolidinone derivatives, also with improved characteristics with respect to linezolid, are presently under study: at least three of them are in an advanced phase of development.
Collapse
|
44
|
Lemaire S, Tulkens PM, Van Bambeke F. Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils. Antimicrob Agents Chemother 2010; 54:2540-8. [PMID: 20385873 PMCID: PMC2876419 DOI: 10.1128/aac.01723-09] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2009] [Revised: 02/21/2010] [Accepted: 03/05/2010] [Indexed: 12/30/2022] Open
Abstract
Radezolid (RX-1741) is the first biaryloxazolidinone in clinical development. It shows improved activity, including against linezolid-resistant strains. Radezolid differs from linezolid by the presence of a biaryl spacer and of a heteroaryl side chain, which increases the ionization and hydrophilicity of the molecule at physiological pH and confers to it a dibasic character. The aim of this study was to determine the accumulation and subcellular distribution of radezolid in phagocytic cells and to decipher the underlying mechanisms. In THP-1 human macrophages, J774 mouse macrophages, and human polymorphonuclear neutrophils, radezolid accumulated rapidly and reversibly (half-lives of approximately 6 min and 9 min for uptake and efflux, respectively) to reach, at equilibrium, a cellular concentration 11-fold higher than the extracellular one. This process was concentration and energy independent but pH dependent (accumulation was reduced to 20 to 30% of control values for cells in medium at a pH of <6 or in the presence of monensin, which collapses pH gradients between the extracellular and intracellular compartments). The accumulation at equilibrium was not affected by efflux pump inhibitors (verapamil and gemfibrozil) and was markedly reduced at 4 degrees C but was further increased in medium with low serum content. Subcellular fractionation studies demonstrated a dual subcellular distribution for radezolid, with approximately 60% of the drug colocalizing to the cytosol and approximately 40% to the lysosomes, with no specific association with mitochondria. These observations are compatible with a mechanism of transmembrane diffusion of the free fraction and partial segregation of radezolid in lysosomes by proton trapping, as previously described for macrolides.
Collapse
Affiliation(s)
- Sandrine Lemaire
- Unité de Pharmacologie cellulaire et moléculaire and Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium
| | - Paul M. Tulkens
- Unité de Pharmacologie cellulaire et moléculaire and Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium
| | - Françoise Van Bambeke
- Unité de Pharmacologie cellulaire et moléculaire and Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium
| |
Collapse
|
45
|
Otto M. Looking toward basic science for potential drug discovery targets against community-associated MRSA. Med Res Rev 2010; 30:1-22. [PMID: 19399829 DOI: 10.1002/med.20160] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The difficulties to find a conventional vaccine against Staphylococcus aureus and the increasing resistance of S. aureus to many antibiotics demand the exploration of novel therapeutic options, such as by targeting virulence determinants and using specific antibodies in an antitoxin-like approach. Community-associated methicillin-resistant S. aureus (CA-MRSA) strains have recently emerged predominantly in the US, causing epidemic outbreaks of mostly skin and soft tissue infections, but also more dramatic and sometimes fatal diseases. MRSA is now the most frequent cause of death by a single infectious agent in the US. The fact that, at least in the US, CA-MRSA infections are almost entirely due to one sequence type, USA300, gives researchers a novel, unique chance to focus on one clone in their efforts to analyze pathogenesis in a clinically important S. aureus. While the molecular underpinnings of the exceptional virulence and transmissibility of USA300 are not yet well understood, recent findings indicate that increased expression of widespread virulence determinants and acquisition of mobile genetic elements have to be considered. Delineating the relative importance of virulence determinants in USA300 and other important clinical strains is a key endeavor needed to develop a potential antitoxin for CA-MRSA disease.
Collapse
Affiliation(s)
- Michael Otto
- Laboratory of Human Bacterial Pathogenesis, National Institute of Allergy and Infectious Diseases, The National Institutes of Health, Bldg. 33 1W10, Bethesda, Maryland 20892, USA.
| |
Collapse
|
46
|
Devasahayam G, Scheld WM, Hoffman PS. Newer antibacterial drugs for a new century. Expert Opin Investig Drugs 2010; 19:215-34. [PMID: 20053150 DOI: 10.1517/13543780903505092] [Citation(s) in RCA: 93] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
IMPORTANCE OF THE FIELD Antibacterial drug discovery and development has slowed considerably in recent years, with novel classes discovered decades ago and regulatory approvals tougher to get. Traditional approaches and the newer genomic mining approaches have not yielded novel classes of antibacterial compounds. Instead, improved analogues of existing classes of antibacterial drugs have been developed by improving potency, minimizing resistance and alleviating toxicity. AREAS COVERED IN THIS REVIEW This article is a comprehensive review of newer classes of antibacterial drugs introduced or approved after year 2000. WHAT THE READER WILL GAIN It describes their mechanisms of action/resistance, improved analogues, spectrum of activity and clinical trials. It also discusses new compounds in development with novel mechanisms of action, as well as novel unexploited bacterial targets and strategies that may pave the way for combating drug resistance and emerging pathogens in the twenty-first century. TAKE HOME MESSAGE The outlook of antibacterial drug discovery, though challenging, may not be insurmountable in the years ahead, with legislation on incentives and funding introduced for developing an antimicrobial discovery program and efforts to conserve antibacterial drug use.
Collapse
Affiliation(s)
- Gina Devasahayam
- University of Virginia, Department of Medicine, Room 2146 MR4 Bldg, 409 Lane Rd, Charlottesville, VA 22908, USA.
| | | | | |
Collapse
|
47
|
Yan S, Miller MJ, Wencewicz TA, Möllmann U. Syntheses and antibacterial activity studies of new oxazolidinones from nitroso Diels-Alder chemistry. Bioorg Med Chem Lett 2009; 20:1302-5. [PMID: 20031407 DOI: 10.1016/j.bmcl.2009.10.018] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2009] [Revised: 10/02/2009] [Accepted: 10/05/2009] [Indexed: 10/20/2022]
Abstract
A series of novel oxazolidinone antibiotics having [2.2.1] and [2.2.2] bicyclic oxazine moieties at the C-5 side chain of the A-ring was synthesized by nitroso Diels-Alder reactions, from three linezolid analogs containing morpholine, piperazine and thiomorpholine, respectively, as the C-ring components. Subsequent N-O bond cleavage generated oxazolidinones with 4-amino cyclo-2-en-1-ol substituents. The in vitro antibacterial activities of these oxazolidinone analogs were evaluated.
Collapse
Affiliation(s)
- Shanshan Yan
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA
| | | | | | | |
Collapse
|
48
|
Fasani E, Tilocca F, Albini A. Photochemistry of Oxazolidinone Antibacterial Drugs. Photochem Photobiol 2009; 85:879-85. [DOI: 10.1111/j.1751-1097.2009.00546.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Phillips OA, Sharaf LH. 5-Hydroxymethyl-oxazolidin-2-one antibacterials. Actelion Pharmaceuticals: WO2008062379. Expert Opin Ther Pat 2009; 19:529-40. [PMID: 19441931 DOI: 10.1517/17530050902800142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The application, WO2008062379, claims chimeric compounds comprising chemically linked 5-hydroxymethyl-oxazolidinone and tetracyclic-quinolone moieties. The claimed compounds are potent expanded-range antibacterial agents against selected gram-positive and gram-negative bacteria, which may exhibit dual mode of action as inhibitors of topoisomarases IV and protein synthesis. The structures of the compounds suggest that the linkers are chemically and biochemically stable. This application represents part of recently initiated research efforts at Actelion.
Collapse
Affiliation(s)
- Oludotun A Phillips
- Kuwait University, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, P.O. Box 24923, Safat 13110, Kuwait.
| | | |
Collapse
|
50
|
Feng J, Lupien A, Gingras H, Wasserscheid J, Dewar K, Légaré D, Ouellette M. Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res 2009; 19:1214-23. [PMID: 19351617 DOI: 10.1101/gr.089342.108] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Linezolid is a member of a novel class of antibiotics, with resistance already being reported. We used whole-genome sequencing on three independent Streptococcus pneumoniae strains made resistant to linezolid in vitro in a step-by-step fashion. Analysis of the genome assemblies revealed mutations in the 23S rRNA gene in all mutants including, notably, G2576T, a previously recognized resistance mutation. Mutations in an additional 31 genes were also found in at least one of the three sequenced genomes. We concentrated on three new mutations that were found in at least two independent mutants. All three mutations were experimentally confirmed to be involved in antibiotic resistance. Mutations upstream of the ABC transporter genes spr1021 and spr1887 were correlated with increased expression of these genes and neighboring genes of the same operon. Gene inactivation supported a role for these ABC transporters in resistance to linezolid and other antibiotics. The hypothetical protein spr0333 contains an RNA methyltransferase domain, and mutations within that domain were found in all S. pneumoniae linezolid-resistant strains. Primer extension experiments indicated that spr0333 methylates G2445 of the 23S rRNA and mutations in spr0333 abolished this methylation. Reintroduction of a nonmutated version of spr0333 in resistant bacteria reestablished G2445 methylation and led to cells being more sensitive to linezolid and other antibiotics. Interestingly, the spr0333 ortholog was also mutated in a linezolid-resistant clinical Staphylococcus aureus isolate. Whole-genome sequencing and comparative analyses of S. pneumoniae resistant isolates was useful for discovering novel resistance mutations.
Collapse
Affiliation(s)
- Jie Feng
- Centre de Recherche en Infectiologie, Québec G1V 4G2, Canada
| | | | | | | | | | | | | |
Collapse
|